Allopurinol Dose Escalation and Mortality Among Patients With Gout

A National Propensity-Matched Cohort Study

Brian W. Coburn, Kaleb D Michaud, Debra A. Bergman, Ted R Mikuls

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: Observational data suggest that hyperuricemia and gout are associated with increased mortality, while allopurinol use is associated with reduced mortality. In addition, the protective effect of allopurinol may be dose dependent. The aim of the current study was to determine whether allopurinol dose escalation is associated with cause-specific mortality in patients with gout. Methods: In this 10-year observational, active-comparator study of US Veterans with gout who initiated treatment with allopurinol, propensity score matching, Cox proportional hazards models, and competing risks regression analyses were used to assess differences in cause-specific mortality between patients whose allopurinol dose was escalated (dose escalators) and those whose allopurinol dose was not escalated or was reduced (non-escalators) over a 2-year period. Results: Among the 6,428 dose escalators and 6,428 matched non-escalators, there were 2,867 deaths during the observation period (40.4 deaths per 1,000 person-years). Dose escalators experienced an increase in all-cause mortality (hazard ratio [HR] 1.08, 95% confidence interval [95% CI] 1.01–1.17), with the effect sizes being similar for incidence of cardiovascular-related deaths (HR 1.08, 95% CI 0.97–1.21) and cancer-related deaths (HR 1.06, 95% CI 0.88–1.27), although neither reached statistical significance. Dose escalation to achieve the goal of lowering the serum urate (SU) level to <6.0 mg/dl was infrequent. At 2 years, 10% of dose escalators were receiving a final daily dose of >300 mg and 31% had achieved the SU goal. In a sensitivity analysis limited to dose escalators achieving the SU goal, there was a nonsignificant reduction of 7% in the hazard of cardiovascular-related mortality (HR 0.93, 95% CI 0.76–1.14). Conclusion: This is the largest study to date to investigate the effects of allopurinol use on mortality and is the first to use a rigorous active-comparator design. Dose escalation was associated with a small (<10%) increase in all-cause mortality, thus showing that a strategy of allopurinol dose escalation, which in current real-life practice is characterized by limited dose increases, is unlikely to improve the survival of patients with gout.

Original languageEnglish (US)
Pages (from-to)1298-1307
Number of pages10
JournalArthritis and Rheumatology
Volume70
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Allopurinol
Gout
Cohort Studies
Elevators and Escalators
Mortality
Uric Acid
Confidence Intervals
Serum
Hyperuricemia
Propensity Score
Veterans
Proportional Hazards Models
Regression Analysis
Observation
Survival
Incidence

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Cite this

Allopurinol Dose Escalation and Mortality Among Patients With Gout : A National Propensity-Matched Cohort Study. / Coburn, Brian W.; Michaud, Kaleb D; Bergman, Debra A.; Mikuls, Ted R.

In: Arthritis and Rheumatology, Vol. 70, No. 8, 01.08.2018, p. 1298-1307.

Research output: Contribution to journalArticle

@article{2a0e38fc48e24df8a7abd4743a5bfaf5,
title = "Allopurinol Dose Escalation and Mortality Among Patients With Gout: A National Propensity-Matched Cohort Study",
abstract = "Objective: Observational data suggest that hyperuricemia and gout are associated with increased mortality, while allopurinol use is associated with reduced mortality. In addition, the protective effect of allopurinol may be dose dependent. The aim of the current study was to determine whether allopurinol dose escalation is associated with cause-specific mortality in patients with gout. Methods: In this 10-year observational, active-comparator study of US Veterans with gout who initiated treatment with allopurinol, propensity score matching, Cox proportional hazards models, and competing risks regression analyses were used to assess differences in cause-specific mortality between patients whose allopurinol dose was escalated (dose escalators) and those whose allopurinol dose was not escalated or was reduced (non-escalators) over a 2-year period. Results: Among the 6,428 dose escalators and 6,428 matched non-escalators, there were 2,867 deaths during the observation period (40.4 deaths per 1,000 person-years). Dose escalators experienced an increase in all-cause mortality (hazard ratio [HR] 1.08, 95{\%} confidence interval [95{\%} CI] 1.01–1.17), with the effect sizes being similar for incidence of cardiovascular-related deaths (HR 1.08, 95{\%} CI 0.97–1.21) and cancer-related deaths (HR 1.06, 95{\%} CI 0.88–1.27), although neither reached statistical significance. Dose escalation to achieve the goal of lowering the serum urate (SU) level to <6.0 mg/dl was infrequent. At 2 years, 10{\%} of dose escalators were receiving a final daily dose of >300 mg and 31{\%} had achieved the SU goal. In a sensitivity analysis limited to dose escalators achieving the SU goal, there was a nonsignificant reduction of 7{\%} in the hazard of cardiovascular-related mortality (HR 0.93, 95{\%} CI 0.76–1.14). Conclusion: This is the largest study to date to investigate the effects of allopurinol use on mortality and is the first to use a rigorous active-comparator design. Dose escalation was associated with a small (<10{\%}) increase in all-cause mortality, thus showing that a strategy of allopurinol dose escalation, which in current real-life practice is characterized by limited dose increases, is unlikely to improve the survival of patients with gout.",
author = "Coburn, {Brian W.} and Michaud, {Kaleb D} and Bergman, {Debra A.} and Mikuls, {Ted R}",
year = "2018",
month = "8",
day = "1",
doi = "10.1002/art.40486",
language = "English (US)",
volume = "70",
pages = "1298--1307",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

TY - JOUR

T1 - Allopurinol Dose Escalation and Mortality Among Patients With Gout

T2 - A National Propensity-Matched Cohort Study

AU - Coburn, Brian W.

AU - Michaud, Kaleb D

AU - Bergman, Debra A.

AU - Mikuls, Ted R

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Objective: Observational data suggest that hyperuricemia and gout are associated with increased mortality, while allopurinol use is associated with reduced mortality. In addition, the protective effect of allopurinol may be dose dependent. The aim of the current study was to determine whether allopurinol dose escalation is associated with cause-specific mortality in patients with gout. Methods: In this 10-year observational, active-comparator study of US Veterans with gout who initiated treatment with allopurinol, propensity score matching, Cox proportional hazards models, and competing risks regression analyses were used to assess differences in cause-specific mortality between patients whose allopurinol dose was escalated (dose escalators) and those whose allopurinol dose was not escalated or was reduced (non-escalators) over a 2-year period. Results: Among the 6,428 dose escalators and 6,428 matched non-escalators, there were 2,867 deaths during the observation period (40.4 deaths per 1,000 person-years). Dose escalators experienced an increase in all-cause mortality (hazard ratio [HR] 1.08, 95% confidence interval [95% CI] 1.01–1.17), with the effect sizes being similar for incidence of cardiovascular-related deaths (HR 1.08, 95% CI 0.97–1.21) and cancer-related deaths (HR 1.06, 95% CI 0.88–1.27), although neither reached statistical significance. Dose escalation to achieve the goal of lowering the serum urate (SU) level to <6.0 mg/dl was infrequent. At 2 years, 10% of dose escalators were receiving a final daily dose of >300 mg and 31% had achieved the SU goal. In a sensitivity analysis limited to dose escalators achieving the SU goal, there was a nonsignificant reduction of 7% in the hazard of cardiovascular-related mortality (HR 0.93, 95% CI 0.76–1.14). Conclusion: This is the largest study to date to investigate the effects of allopurinol use on mortality and is the first to use a rigorous active-comparator design. Dose escalation was associated with a small (<10%) increase in all-cause mortality, thus showing that a strategy of allopurinol dose escalation, which in current real-life practice is characterized by limited dose increases, is unlikely to improve the survival of patients with gout.

AB - Objective: Observational data suggest that hyperuricemia and gout are associated with increased mortality, while allopurinol use is associated with reduced mortality. In addition, the protective effect of allopurinol may be dose dependent. The aim of the current study was to determine whether allopurinol dose escalation is associated with cause-specific mortality in patients with gout. Methods: In this 10-year observational, active-comparator study of US Veterans with gout who initiated treatment with allopurinol, propensity score matching, Cox proportional hazards models, and competing risks regression analyses were used to assess differences in cause-specific mortality between patients whose allopurinol dose was escalated (dose escalators) and those whose allopurinol dose was not escalated or was reduced (non-escalators) over a 2-year period. Results: Among the 6,428 dose escalators and 6,428 matched non-escalators, there were 2,867 deaths during the observation period (40.4 deaths per 1,000 person-years). Dose escalators experienced an increase in all-cause mortality (hazard ratio [HR] 1.08, 95% confidence interval [95% CI] 1.01–1.17), with the effect sizes being similar for incidence of cardiovascular-related deaths (HR 1.08, 95% CI 0.97–1.21) and cancer-related deaths (HR 1.06, 95% CI 0.88–1.27), although neither reached statistical significance. Dose escalation to achieve the goal of lowering the serum urate (SU) level to <6.0 mg/dl was infrequent. At 2 years, 10% of dose escalators were receiving a final daily dose of >300 mg and 31% had achieved the SU goal. In a sensitivity analysis limited to dose escalators achieving the SU goal, there was a nonsignificant reduction of 7% in the hazard of cardiovascular-related mortality (HR 0.93, 95% CI 0.76–1.14). Conclusion: This is the largest study to date to investigate the effects of allopurinol use on mortality and is the first to use a rigorous active-comparator design. Dose escalation was associated with a small (<10%) increase in all-cause mortality, thus showing that a strategy of allopurinol dose escalation, which in current real-life practice is characterized by limited dose increases, is unlikely to improve the survival of patients with gout.

UR - http://www.scopus.com/inward/record.url?scp=85050471369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050471369&partnerID=8YFLogxK

U2 - 10.1002/art.40486

DO - 10.1002/art.40486

M3 - Article

VL - 70

SP - 1298

EP - 1307

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 8

ER -